Celltrion

Celltrion, a Pharmaceutical Preparation Manufacturing company based in KR, reported its 2024 Scope 1 emissions at 27,146,000 kg CO2e and its Scope 2 emissions (location-based) at 52,028,000 kg CO2e. The company also disclosed its 2024 Scope 3 emissions, which totalled 42,426,000 kg CO2e. Key Scope 3 categories included 986,000 kg CO2e from capital goods, 3,500,000 kg CO2e from business travel, 700,000 kg CO2e from employee commuting, 3,202,000 kg CO2e from purchased goods and services, 4,464,000 kg CO2e from waste generated in operations, 18,122,000 kg CO2e from upstream transportation and distribution, and 26,939,000 kg CO2e from downstream transportation and distribution.

In 2023, Celltrion's Scope 1 emissions were 22,457,000 kg CO2e, and Scope 2 emissions (location-based) were 42,260,000 kg CO2e. Their Scope 3 emissions for 2023 amounted to 28,798,000 kg CO2e, including 714,000 kg CO2e from capital goods, 2,112,000 kg CO2e from business travel, 618,000 kg CO2e from employee commuting, 4,558,000 kg CO2e from purchased goods and services, 3,035,000 kg CO2e from waste generated in operations, 14,287,000 kg CO2e from upstream transportation and distribution, and 16,136,000 kg CO2e from downstream transportation and distribution.

Celltrion has set an absolute target to reduce its Greenhouse Gas (GHG) emissions by 50% by 2030, using 2020 as a baseline. The company is also working towards achieving carbon neutrality by 2050 for all scopes. Furthermore, Celltrion has committed to mitigating Scope 1 and 2 emissions by 42% by 2030 and by 100% by 2045, with a 2022 base year, across its domestic operations including Celltrion and Celltrion Pharm.